Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esaú Fernández-Pascual has a total of 185 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development and Preliminary Validation of a Male‐Oriented Fertility Index in Infertile Men With Varicocele

    by Azizbek Shomarufov, Vladimir Bozhedomov, Marlon Martinez, Esaú Fernández‐Pascual

    Background: Male infertility is usually assessed using separate parameters, while a simple integrated male‐oriented tool is lacking. Objectives: To develop a Male Fertility Index (MFI), assess its association with natural conception after varicocelectomy, and perform preliminary external validation. Materials and Methods: This two‐center cohort study included 149 infertile men with clinical varicocele: 99 in the development cohort and 50 in the validation cohort. Preoperative variables were analyzed against natural conception within 12 months. ROC‐derived AUCs for total progressively motile sperm count, total motility, male age, and infertility duration were used to construct the MFI. Results: Natural conception occurred in 30/99 couples (30.3%). MFI values were higher in men whose partners conceived (1.44 [0.87–2.15] vs. 0.64 [0.25–1.31], p < 0.001). Conception was more frequent with MFI > 0.8 than with MFI ≤ 0.8 (44.4% vs. 13.3%, p = 0.0017). In validation, corresponding rates were 40.0% and 14.3%; AUC was 0.795 (95% CI 0.650–0.911). Discussion: The MFI showed a similar association with natural conception in both cohorts, although validation was limited by sample size and incomplete assessment of female factors. Conclusion: The MFI may summarize male reproductive status in infertile men with clinical varicocele. Its weighting and cut‐off require confirmation in larger cohorts, and its usefulness in other infertility settings remains to be established.

  • Radiofrequency-based therapies for male sexual dysfunctions: a systematic scoping review of clinical evidence and the emerging trial landscape

    by Giuseppe Maiolino, Carlos Balmori, Esaú Fernández-Pascual, Enrique Lledó-García, Álvaro Navas Mosqueda, Juan Ignacio Martínez-Salamanca

    Introduction: Radiofrequency (RF)-based therapies have emerged as potential treatments for male sexual dysfunctions (MSDs), including erectile dysfunction (ED), Peyronie’s disease (PD), and premature ejaculation (PE). However, available technologies, treatment protocols, and clinical indications are highly heterogeneous. Methods: PubMed, Embase, Web of Science, and ClinicalTrials.gov were systematically searched through April 21, 2026. Peer-reviewed clinical studies evaluating RF-based interventions for ED, PD, or PE were included in the clinical evidence synthesis, while registered trials without peer-reviewed published outcomes identified at the time of the search were described separately. Findings were synthesized narratively, and risk of bias was assessed according to study design. Results: Ten published clinical studies were included in the evidence synthesis: 3 in ED, 4 in PD, and 3 in PE, comprising 456 participants enrolled or randomized, of whom 447 contributed outcome data where analyzable sample sizes were reported. The interventions encompassed distinct RF modalities, including external capacitive–resistive RF, self-applied low-intensity RF, multimodal RF-based therapy, and percutaneous pulsed RF neuromodulation. Short-term improvements were reported in erectile-function outcomes in ED, pain in PD, and intravaginal ejaculatory latency time in PE. However, the evidence was limited by small sample sizes, substantial heterogeneity in RF technologies and treatment protocols, brief follow-up, variable control conditions, and frequent use of combined interventions. No serious treatment-related adverse events were reported in the available studies, although safety data were limited by small cohorts and short follow-up. Risk-of-bias assessment identified important methodological concerns. Five additional registered trials were identified and described separately. Conclusions: Current evidence is insufficient to establish the efficacy of RF-based therapies for MSDs. Reported short-term improvements should be interpreted cautiously, and RF-based interventions should remain investigational until adequately powered, sham-controlled trials with standardized, technology-specific protocols and longer follow-up establish treatment-specific efficacy, durability, and safety.

  • Efficacy and safety of hyaluronic acid and enzymatic mix intralesional therapy in Peyronie's disease: a prospective, randomized, controlled pilot study of outcomes and patient satisfaction

    by Esaú Fernández-Pascual, Giuseppe Maiolino, Luiz Pedro Palma-Hendges, Carmen Sánchez de la Morena, Pablo Solano-Heranz, Luis Martínez-Piñeiro, Enrique Lledó–García, Juan Ignacio Martínez-Salamanca

    Introduction: Peyronie’s disease (PD) is characterized by fibrotic plaque formation leading to penile curvature. Xiapex’s 2020 withdrawal from Europe eliminated validated intralesional therapies. This study evaluated the efficacy and safety of an intralesional hyaluronic acid-enzymatic mix (Fibrorestil: 0.05% sodium hyaluronate + recombinant collagenase/lyase/lipase) added to daily tadalafil and penile traction versus conservative therapy alone in men with stable-phase PD. Methods: This prospective, randomized, open-label, multicenter pilot trial (June 2023-March 2025; ClinicalTrials.gov NCT07341529; HUPHM-85-21) enrolled 38 men with stable PD, palpable plaque, and 30°–90° curvature. Group A received three intralesional sessions with plaque tunneling plus Andropenis extender (≥4 hours/day) and tadalafil (2.5-5 mg/day). Group B received traction and tadalafil (conservative therapy) alone. Assessments were performed at baseline and week 28. Analyses used intention-to-treat (n = 38) and per-protocol (n = 34) approaches, with Mann–Whitney U tests. Primary outcomes were absolute and relative curvature change (responders ≥15° improvement). Secondary outcomes included Peyronie’s Disease Questionnaire (PDQ) changes; IIEF-EF minimal clinically important difference; satisfaction; and Clavien-Dindo adverse events. Results: Baseline curvatures was higher in Group A (60° [50;70] vs 45° [30;60], P = .037) with Group B showing more diabetes, numerically more hourglass deformity and calcified plaques, and shorter disease duration. Per-protocol curvature change was -15.0° [-20.0; -10.0] (27.3%; 52.9% responders) in Group A versus 0.0° in Group B (P = .001); final curvature was comparable (50° vs 45°, P = .786). ANCOVA adjusting for baseline curvature showed an adjusted between-group difference of 14.1° (P = .001). An exploratory multivariable model additionally adjusting for diabetes, calcification, disease duration, and hourglass deformity attenuated this effect (−6.1°, 95% CI −17.7 to 5.5; P = .288); given the small sample relative to covariates, this estimate is statistically fragile and hypothesis-generating rather than confirmatory. PDQ symptom-bother improved significantly in Group A [-1.5; P = .003], with numerical gains in total [-6.0 vs -2.5; P = .149] and physical-psychological [-3.5 vs -1.0; P = .110] domains. Satisfaction (“satisfied/very satisfied”) was reported by 70.6% of Group A versus 11.8% of Group B (P = .001). Extender adherence >4 hours/day predicted response (88.9% vs 12.5%; P = .003). Only mild (Clavien-Dindo I) adverse events occurred (36.8% in Group A versus 5.3%). Conclusion: Fibrorestil intralesional therapy demonstrates possible improvements in curvature and patient-reported outcomes versus conservative care in stable-phase PD and appears safe, while conservative care alone showed no meaningful improvement. Given baseline imbalances, small pilot sample size, open-label design, and lack of an equivalent sham injection control, these findings should be considered exploratory and require confirmation in larger randomized trials.

  • Open Access

    Peyronie’s disease in Spain: a prospective study

    by François Peinado-Ibarra, Borja García-Gómez, Manuel Alonso-Isa, Carlos Simón-Rodríguez, Juan García-Cardoso, Josep Torremadé-Barreda, Félix Campos-Juanatey, Rodrigo García-Baquero, Mario Álvarez-Maestro, Esaú Fernández-Pascual, et al.

    Background: Peyronie’s disease (PD) research has limitations due to heterogeneity in time of presentation, severity, deformity characteristics, and associated conditions. Aim: To provide further insight into clinical characteristics of patients, PD treatments and patient perceptions of outcomes in clinical practice in Spain. Methods: A total of 601 men from 15 Spanish andrology centers were included in this observational, prospective multicenter cohort study. Enrolled patients (aged ≥18 years with confirmed PD diagnosis, naïve to specific therapy and without congenital penile curvature) were evaluated by detailed medical history and physical examination including plaque characteristics and curvature. Sexual function was assessed by the International Index of Erectile Function-5 and the Peyronie’s Disease Questionnaire. The characteristics of treatment used for PD as well as patient subjective outcomes were analyzed in cases involving curvature assessments. Outcomes: The primary outcome was demographic and clinical characterization of PD patients; secondary outcomes included PD treatment used in clinical practice and patient satisfaction. Results: The median age (interquartile range, IQR) was 57 (49.0-63.0) years with a median duration of PD of 12 (6.0-18.0) months. There were 246 (41.6%) patients in the acute phase of the disease. The most common nonsurgical treatments were traction therapy (36.0%), collagenase injections (29.3%), and daily tadalafil (22.7%). The most frequently used surgical technique was penile plication (62.3%) followed by grafting and plaque incision (34.0%). The median Peyronie’s Disease Questionnaire and International Index of Erectile Function-5 scores were 19.0 (12.0-28.0) and 18.0 (13.0-22.5), respectively. Curvature assessment was performed in 331 patients, using the Kelami test in 316 (96.0%) or intracavernous injection of a vasoactive agent in 143 (45.5%). Clinical implications: Many patients are misdiagnosed, and treatment may take a long time; understanding the profile of PD, as well as satisfaction with real-life treatment outcomes, can aid clinicians in selecting more appropriate treatments. Strengths and Limitations: As a free collaborative registry, not all patient data were collected, and therefore not all data were available throughout the study, and a longer follow-up period would have given us more information to compare the pretreatment and post-treatment situations. However, this study provides a description of clinical characteristics of a large real-world cohort of men with PD from a considerable number of sites nationwide. Conclusions: We found a wide variety of treatments used in clinical practice, including those with poor evidence of efficacy, which suggests the need for a better understanding of PD for developing the most effective treatment protocol.

  • Multimodal electrostimulation in erectile dysfunction: preliminary experience with the NeuroEstimulación Ecoguiada Percutánea Transcavernosa del Pudendo technique

    by Álvaro Navas Mosqueda, Giuseppe Maiolino, Gracia Gallego Sendarrubias, Borja García-Gómez, Juan Ignacio Martínez-Salamanca, Enrique Lledó Garcia, Eldiberto Manuel Fernández Fernández, Javier Romero Otero, Eduardo Cimadevilla Fernández-Pola, Roi Fernández Dios, et al.


  • Nocturnal emissions or wet dreams: modern evidence from a systematic scoping review

    by Giuseppe Maiolino, Esaú Fernández-Pascual, Enrique Lledó-García, Juan Ignacio Martínez-Salamanca

    Introduction: Nocturnal emissions (NEs), or “wet dreams,” are involuntary ejaculations occurring during sleep. Although NEs are a normal component of male puberty, uncertainties have persisted regarding their physiology, epidemiology, and clinical significance. Objectives: To systematically review the literature on NEs, summarizing epidemiological data, physiological mechanisms, cultural perspectives, and clinical relevance. Methods: A systematic search of PubMed and EMBASE (from inception to April 2025) was performed. Grey literature was included to minimize publication bias, and non-English studies were translated. The FAERS and EudraVigilance databases were queried for drug-related NEs. No exclusions were made based on study design. The risk of bias was assessed with the Newcastle–Ottawa Scale, and qualitative works were appraised narratively. Results: A total of 157 sources were included. The first NE typically occurs between 12.6 and 15.6 years, most often at 13-14, with modest cross-cultural variation. Prevalence resulted high (70%-90%), especially among adolescents, though lower in some Asian cohorts and rare in individuals with neurological impairment. Data on frequency were scarce and inconsistent. Educational gaps were evident and misconceptions remain widespread, particularly in South Asia, where NEs are central to Dhat syndrome. Evidence did not support the historical view of NEs as a compensatory release under conditions of low sexual outlet. NEs occurred with or without erotic dreams. Findings from studies on spinal cord injury and psychogenic anejaculation confirm that they can arise independently of supraspinal control. Their association with sleep orgasms and sleep-related erections remained uncertain. Hormonal, parental, and prenatal influences appeared modest. NEs may help in differentiating psychogenic anejaculation and occasionally serve as a sperm source for assisted reproduction. Conclusion: NEs are a nearly universal, physiological phenomenon with cultural, educational, and clinical dimensions and they remain relevant to sexual development, adolescent health, and certain diagnostic contexts. High-quality prospective research is needed to clarify mechanisms and implications.


  • Efficacy and safety of two disposable circumcision suture devices for circumcision in adults: a prospective comparative multicenter study

    by Alessia Celeste Bocchino, Esaú Fernández-Pascual, Carlos Toribio-Vázquez, Celeste Manfredi, Guillermo Urdaneta, Carlos Balmori, Enrique Lledó, Claudio Martínez-Ballesteros, Andrea Cocci, Nicola Mondaini, et al.

    The objective of this study was to evaluate and compare efficacy and safety of two different Disposable circumcision suture devices (DCSDs). A prospective comparative non-randomized multicenter study was performed between November 2019 and February 2023. Patients underwent circumcision using a DCSD (CircCurerTM or the ZSR® device) according to the surgeon preference and device availability. A total of 378 patients were circumcised; 184 using CircCurerTM and 194 patients using ZSR®. No differences in baseline characteristics were observed. CircCurer and ZSR Groups showed similar rates of operative time (7.7 ±2.1 vs 7.3 ±2.0 min), surgical site infection (1.1% Vs 1.5%), edema (13% Vs 8.2%), hematomas (2.7% Vs 1.1%), and postoperative pain (2.5 Vs 2.0 points). ZSR Group had a significantly higher rate of clip fallout (62.9% Vs 38%, p < 0.001). At 2 months, patients of both groups reported a median satisfaction of 9 (8–9) points. Main limitation consist in non-randomized study. DCSDs seem to be effective and safe, with short operative times, uncommon and mild complications, and high patient satisfaction. ZSR® device has a higher rate of spontaneous staple dropout.


  • Open Access

    Cell therapy for male sexual dysfunctions: systematic review and position statements from the European Society for Sexual Medicine

    by Celeste Manfredi, Luca Boeri, Ioannis Sokolakis, Nicolò Schifano, Nikolaos Pyrgidis, Esaú Fernández-Pascual, Andrea Sansone, Borja García-Gómez, Maarten Albersen, Giovanni Corona, et al.

    Background: Cell therapy (CT) is a form of regenerative medicine under investigation for the management of male sexual dysfunction (MSD). Aim: We sought to perform a systematic review of published information on CT for MSD and provide an official position statements for the European Society for Sexual Medicine. Methods: A comprehensive bibliographic search on the MEDLINE, Web of Science, Scopus, and Cochrane Library databases was conducted in February 2023. Articles were selected based on the Population, Intervention, Comparator, Outcome, Study design (PICOS) model if they included male patients (P) undergoing CT (I) with or without comparison with other treatments (C) and evaluated the impact of CT on sexual function (O). Quantitative data were reported as found in the original studies (S). Level of evidence and grade of recommendation according to the Oxford Centre for Evidence-Based Medicine were assigned to each statement. Outcomes: Outcomes were determined based on assessment of erectile function, ejaculatory function, orgasmic function, sexual desire, and penile curvature. Results: A total of 19 studies and 421 patients were included. Most articles (n = 12, 63%) were case series, whereas a minority of papers (n = 6, 32%) had a comparative group; only 2 articles reported randomized controlled trials (RCTs) and 1 article reported a post hoc analysis of RCTs. Most articles (16, 84%) investigated patients with erectile dysfunction (ED). Improvements in the International Index of Erectile Function–Erectile Function Domain (IIEF-EF) or the IIEF 5-item version (IIEF-5) were found in 11/15 (73%) studies, with mean increases in IIEF-EF, mean IIEF-5, and median IIEF-EF between 8 and 14 points, 2 and 9 points, and 4.5 and 6 points, respectively. Two papers (20%) evaluated men with Peyronie’s disease (PD). In both ot these articles penile curvature improvement and plaque volume reduction were described in all patients (n = 16, 100%). Objective measurements were performed in 1 study, which showed 10°-120° (15%-100%) curvature improvement and 90%-100% plaque reduction. Mild transient adverse events at the donor or administration sites were found in 7/16 (44%) papers on ED. Priapism was reported in one case (20%) and mild penile skin complications were reported in the majority of patients after CT for PD. No severe adverse events were described. Clinical Implications: Although high-quality evidence is lacking, CT appears to have potential benefits from application in patients with ED or PD. Strengths and Limitations: This report is to our knowledge the most comprehensive and up-to-date systematic review on the topic of CT for the management of MSD, including the position statements of the European Society for Sexual Medicine. Overall the assessment of available studies demonstrated low quality and significant heterogeneity. Conclusion: Preliminary findings support potential efficacy and safety of CT in patients with ED or PD. Low-quality papers, high methodological heterogeneity, uncertainty about the magnitude of the beneficial effects, and lack of long-term data limit the available evidence.


  • Correction: Peyronie’s Disease Questionnaire (PDQ): Spanish translation and validation

    by Borja García-Gómez, Juan Ignacio Martínez-Salamanca, Joaquim Sarquella-Geli, Juan Justo-Quintas, Esther García-Rojo, Esaú Fernández-Pascual, Eduard Ruíz-Castañé, Javier Romero-Otero